ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

CORNEA is a prestigious peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the rapidly advancing field of ophthalmology with a particular emphasis on corneal research and diseases. With an impact factor categorized in the prestigious Q1 quartile for its discipline, CORNEA has established itself as a leading platform for the dissemination of both fundamental and clinical studies since its inception in 1982. The journal is ranked 25th out of 137 in the Scopus Medicine-Ophthalmology category, placing it in the 82nd percentile among its peers, which underscores its vital role in influencing ocular research and clinical practices. While the journal is not currently open access, it provides valuable insights and updates for professionals, researchers, and students working to advance knowledge in corneal health, contributing significantly to the ongoing dialogue in the ophthalmological community. With a commitment to excellence, CORNEA continues to publish high-quality research and reviews in its pursuit to improve ocular outcomes and patient care.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

EXPERIMENTAL EYE RESEARCH, published by Academic Press Ltd - Elsevier Science Ltd, is a preeminent journal dedicated to advancing the fields of ophthalmology and neuroscience. With a history of insightful publications dating back to 1961, this journal serves as a critical platform for researchers, professionals, and students interested in the cellular and molecular mechanisms underlying visual processes. The journal boasts impressive rankings, including being placed in the top quartile (Q1) of both the Ophthalmology and Sensory Systems categories, and is recognized in the 2nd quartile (Q2) for Cellular and Molecular Neuroscience. With an impact factor reflecting its significant contribution to the field, EXPERIMENTAL EYE RESEARCH is a valuable resource that promotes the exchange of innovative research and ideas essential for understanding the complexities of eye function and vision-related disorders. Researchers looking to publish their findings or stay abreast of the latest studies will find this journal a vital component of their academic toolkit.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Therapeutic Advances in Ophthalmology is a leading open-access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of ocular diseases. Since its inception in 2018, this journal has swiftly gained prominence within the ophthalmology community, proudly holding a Q1 designation in the 2023 category quartiles and ranking 34 out of 137 in the Scopus Medicine_Ophthalmology category, placing it in the top 75th percentile. By providing a platform for innovative research, clinical advancements, and educational resources, Therapeutic Advances in Ophthalmology serves as an essential resource for researchers, healthcare professionals, and students in the field. With a commitment to disseminating high-quality research accessible to all, this journal plays a critical role in shaping the future of ophthalmic care and treatment, enabling professionals to stay abreast of the latest developments and best practices in the discipline.

Ophthalmic Research, with ISSN 0030-3747 and E-ISSN 1423-0259, is a distinguished peer-reviewed journal published by Karger in Switzerland. Established in 1970, this journal serves as a vital resource for exploration and dissemination of knowledge within the fields of Ophthalmology, Cellular and Molecular Neuroscience, and Sensory Systems, maintaining its relevance through its convergence into modern research methodologies leading up to 2024. With impressive rankings in 2023, it holds a Q2 quartile in both Ophthalmology and Medicine (miscellaneous), reflecting its significant contribution to the academic community, alongside Scopus ranks that position it favorably in the competitive landscape of medical and neuroscientific literature. Although not open access, the journal ensures that high-quality research remains accessible to its readership, which includes researchers, professionals, and students eager to stay at the forefront of ophthalmic advancements. By fostering interdisciplinary collaboration and facilitating high-level discourse, Ophthalmic Research is pivotal for those committed to advancing the future of eye care and vision sciences.